Jefferson study shows women with inherited breast cancer gene at greater risk for recurrence and new tumors

The results pose new questions regarding treatment options for women

For many women under 40 with breast cancer, surgery to remove the cancerous lump and accompanying radiation seem the best way to get rid of the disease and preserve the natural breast. But for women who carry a damaged version of BRCA1 or BRCA2, genes predisposing them to breast cancer, such treatment may not be enough. Researchers at Jefferson Medical College have found that such women have a greater risk of either relapsing or developing new tumors years later than those women who receive a lumpectomy and radiation therapy but don't carry one of these genes.

As a result, says Bruce Turner, M.D., Ph.D., assistant professor of radiation oncology at Thomas Jefferson University in Philadelphia and a member of Jefferson's Kimmel Cancer Center, who led the work, women and physicians may want to rethink their treatment options.

"These findings suggest that a woman who has a mutation in BRCA1 or BRCA2 who is treated with breast-conserving therapy not only has a high risk of local recurrence--40 percent according to our study--but also a high risk of developing breast cancer in the other breast as well," Dr. Turner says.

"Our data suggest that breast-conserving therapy may not be the most optimal treatment for breast cancer patients with BRCA1 or BRCA2 mutations who want to reduce the risk of locally recurrent breast cancer."

Dr. Turner and colleagues at Yale University and Myriad Genetics report their findings in the October issue of the Journal of Clinical Oncology.

Of 170,000 new breast cancer cases a year in U.S. women, about 10 percent--17,000 women--are under 40. Some 10 to 15 percent of those women (2,000) carry an altered BRCA1 or BRCA2 gene, and about 70 to 80 percent develop breast cancer.

Dr. Turner and his group wanted to exam

Contact: Steve Benowitz
Thomas Jefferson University

Page: 1 2 3

Related biology news :

1. Jefferson Lab detector technology aids development of cystic fibrosis therapy
2. Jefferson scientists find gene expression pattern may predict behavior of leukemia
3. Jefferson researchers develop microchip to track genetic signature of cancer and normal tissue
4. Jefferson scientists use gene therapy to restore function of damaged heart cells in lab
5. Jefferson researchers uncover biochemical clues to how cells migrate in embryos
6. Jefferson and Brigham and Womens researchers find blue light important for setting biological clock
7. Jefferson Lab experiment generates THz radiation 20,000 times brighter than anyone else
8. Jefferson scientists show neural stem cells can become dopamine-making brain cells in laboratory
9. Jefferson scientists show how collagen gene mutation leads to osteoarthritis
10. Jefferson scientists use gene repair technique to change albino mice hairs to black
11. Jefferson scientists show drug is effective against a Hepatitis C Virus model in the laboratory

Post Your Comments:

(Date:6/21/2016)... 21, 2016 NuData Security announced today that ... of principal product architect and that Jon ... customer development. Both will report directly to ... moves reflect NuData,s strategic growth in its product ... customer demand and customer focus values. ...
(Date:6/16/2016)... FRANCISCO , June 16, 2016 ... size is expected to reach USD 1.83 ... by Grand View Research, Inc. Technological proliferation and ... banking applications are expected to drive the market ... ) , The development of advanced ...
(Date:6/9/2016)... an innovation leader in attendance control systems is proud to announce the introduction of ... make sure the right employees are actually signing in, and to even control the ... ... ... ...
Breaking Biology News(10 mins):
(Date:6/27/2016)... 2016 /PRNewswire/ - BIOREM Inc. (TSX-V: BRM) ("Biorem" or "the ... major shareholders, Clean Technology Fund I, LP and Clean ... based venture capital funds which together hold approximately ... fully diluted, as converted basis), that they have entered ... equity holdings in Biorem to TUS Holdings Co. Ltd. ...
(Date:6/27/2016)... N.C. (PRWEB) , ... June 27, 2016 , ... ... commercial operations for Amgen, will join the faculty of the University of ... as adjunct professor of strategy and entrepreneurship at UNC Kenan-Flagler, with a focus ...
(Date:6/24/2016)... , ... June 24, 2016 , ... While the majority ... as the Cary 5000 and the 6000i models are higher end machines that use ... height of the spectrophotometer’s light beam from the bottom of the cuvette holder. ...
(Date:6/23/2016)... /PRNewswire/ - FACIT has announced the creation of ... company, Propellon Therapeutics Inc. ("Propellon" or "the Company"), ... portfolio of first-in-class WDR5 inhibitors for the treatment ... represent an exciting class of therapies, possessing the ... cancer patients. Substantial advances have been achieved with ...
Breaking Biology Technology:
Cached News: